Data edition of
Residue An evidence-graded reference for peptide science

Bremelanotide clinical trials

Every study registered on ClinicalTrials.gov that lists Bremelanotide as an intervention, as of the data edition — what is being tested, in whom, by whom, and how far it has got.

Registered studies
10
Active or recruiting
1
Completed
9
With posted results
4
Planned or actual enrollment
2,644participants, summed
Registered studies of Bremelanotide by phase and status
PhaseStudiesBreakdown
Phase 1 1
1 completed, 0 active or recruiting, 0 stopped, 0 other
Phase 2 4
3 completed, 1 active or recruiting, 0 stopped, 0 other
Phase 3 3
3 completed, 0 active or recruiting, 0 stopped, 0 other
Phase 4 2
2 completed, 0 active or recruiting, 0 stopped, 0 other
Figure 1. 10 studies on ClinicalTrials.gov match the registry search bremelanotide OR PT-141. Multi-phase studies are counted at their highest phase. Open the full trial feed

Conditions studied

  1. Hypoactive Sexual Desire Disorder5
  2. Obesity1
  3. Female Sexual Arousal Disorder1
  4. Nausea1
  5. Lactating Mother1
  6. Sexual Arousal Disorder1
  7. Kidney Disease1

Lead sponsors

  1. Palatin Technologies, Inc6
  2. Imperial College Healthcare NHS Trust1
  3. Kwang Dong Pharmaceutical co., ltd.1
  4. AMAG Pharmaceuticals, Inc.1
  5. Cosette Pharmaceuticals, Inc.1

The registry, study by study

Registration is not evidence of benefit; many registered studies never publish. Status and dates are as reported by sponsors to ClinicalTrials.gov.

Status
Phase

10 shown

Registered studies of Bremelanotide
StudyPhaseStatusStartnSponsor
NCT06565611A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity Phase 2 Active, not recruiting Aug 2024 108 Palatin Technologies, Inc
NCT06867835Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk Phase 4 Completed Jul 2025 10 Cosette Pharmaceuticals, Inc.
NCT05709444A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Phase 2 Completed Dec 2022 16 Palatin Technologies, Inc
NCT04943068A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) Phase 3 Completed May 2021 193 Kwang Dong Pharmaceutical co., ltd.
NCT04179734Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire DisorderResults posted Phase 4 Completed Oct 2019 40 Imperial College Healthcare NHS Trust
NCT03973047Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran Phase 1 Completed Jun 2019 228 AMAG Pharmaceuticals, Inc.
NCT023389602. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderResults posted Phase 3 Completed Jan 2015 714 Palatin Technologies, Inc
NCT023330711. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderResults posted Phase 3 Completed Dec 2014 723 Palatin Technologies, Inc
NCT01382719Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderResults posted Phase 2 Completed Jun 2011 612 Palatin Technologies, Inc
NCT00425256Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) Phase 2 Completed Feb 2006 — Palatin Technologies, Inc

Run this search on ClinicalTrials.gov → Query term: bremelanotide OR PT-141